Source: Last quarter, we closed a $14.2B healthcare merger between BioCrest Labs and OncoPharm Therapeutics—two biotech rivals with complementary oncology pipelines. It almost collapsed twice: once over IP valuation and again at the final regulatory approval stage. I spent three sleepless days in a conference room, fueled by espresso and sheer determination, hammering out a resolution. The WSJ called it 'the deal that reshaped modern cancer treatment.'
Answer: OncoPharm